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EDITORIAL ARTICLE  
RNA-MODIFYING ENZYMES AS NOVEL TARGETS FOR ANTI-CANCER THERAPIES 
Cancer is a group of diseases whereby a group of cells escape biological mechanisms that control homeostasis and proli-
ferate uncontrollably. Cancer cells have the ability to invade surrounding tissues and to spread through the vasculature to 
distant organs, a property that distinguishes them from benign tumor cells, the latter being incapable of invasion.1 The 
transformation of normal cells to cancer cells requires the presense of genetic mutations. These mutations often occur in 
DNA sequences that encode genes important for tumor progression (oncogenes) or genes that repress tumorigenic po-
tential (tumor suppressor genes). Thus, a combination of mutations that results in gain of function of oncogenes and loss 
of function of tumor suppressor genes confers growth advantage to cancer cells over normal cells. Genetic mutations in 
cancer can be found in the form of gene amplifications or deletions, gene rearrangements or point mutations.2 For 
example, gene amplification lead to high copy number and increased expression levels of oncogenes. On the other hand, 
gene deletions of tumor suppressor genes prevent their expression and shut down their protective mechanisms against 
tumor onset. Different types of gene rearrangement result in the formation of gene fusions, consisted of fragments of two 
different genes. This gives rise to chimeric genes in which one fragment possess the pro-tumorigenic function and the 
second fragment contributes to the constitutive expression of the first, leading to high expression and activity of an onco-
gene. Point mutations refer to single nucleotide mutation in DNA, that results in a substitution of an amino acid in the 
protein generated by this gene. This single amino acid change can confer a gain of function in an oncogene or a loss of 
function in a tumor suppressor gene.   
Apart from genetic mutations, another major factor that contributes to tumorigenesis is the epigenetic landscape in a 
given cell. In that case, epigenetics refers to changes of gene function that are not associated to alterations in DNA se-
quences. Epigenetic modifications occur in the form of DNA methylation, as well as methylation or acetylation of histones, 
the proteins that bind tightly DNA, forming the chromatin. Epigenetic modifications affect chromatin conformation and 
are capable of creating open and closed chromatin. Open chromatin means that the genomic region is accessible to fac-
tors (proteins) that regulate the expression of a gene. In contrast, closed chromatin is compact and not accessible to these 
factors. For example, in cancer, open chromatin is frequently observed nearby oncogenes, leading to their increased ex-
pression levels. On the contrary, many tumor suppressor genes are epigenetically silenced, due to their compact chroma-
tin.3  
Another layer of gene expression regulation takes place at the RNA level. RNA molecules are transcribed from DNA and 
are usually modified at specific bases. These, so called, epitranscriptomic modifications include methylation, pseudouridi-
nation, inosine-to-adenine editing and more. The most abundant RNA modification is the N6-methyladenosine (m6A), as 
it is estimated that around 25% of RNAs bear the m6A marker, genome-wide. The m6A regulators are the “writers”, en-
zymes that catalyze m6A deposition to RNA, the “erasers”, enzymes that remove the modification and the “readers”, pro-
teins which recognize and “interpret” the modification.4 M6A has been detected in several types of RNAs. The molecular 
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functions of m6A RNA methylation has been mainly explored in the case of messenger RNAs (mRNAs), whereby it has 
been demonstrated that it affects several properties of mRNAs, such as splicing, stability/degradation, nuclear export and 
translation to proteins.5 Thus, by modulating biochemical properties of mRNAs, m6A deposition influences gene expres-
sion and therefore it is crucial for many physiological processes. In addition, recent studies provide evidence for critical 
roles of m6A in tumorigenesis, by modulating cell proliferation, invasion, metastasis or immune evasion.6 
During the last years, many studies have unraveled novel roles for m6A regulators in cancer progression. The most impor-
tant m6A regulators are the methyltransferases METTL3 and METTL14, which transfer a methyl group to target RNAs, the 
erasers FTO and ALKBH5, which remove the methyl group from methylated RNAs and numerous proteins (such as 
YTHDC2, YTHDF1, YTHDF2) that recognize and bind m6A-modified RNAs. Interestingly, the expression of the genes enco-
ding these proteins is frequently altered in cancer.7 For example, METTL3 is highly expressed in acute myeloid leukaemia 
(AML), breast and prostate cancers. In these cancers, METTL3 exerts pro-oncogenic functions. In glioblastoma and hepa-
tocellular carcinoma (HCC) both pro- and anti-tumorigenic properties have been attributed to METTL3. On the other 
hand, in endometrial cancer and in renal cell carcinoma METTL3 is mainly anti-tumorigenic. Similarly, the erasers FTO and 
ALKBH5 have been found to be over-expressed in some or under-expressed in other types of cancer.8 Thus, m6A regula-
tors can have dual function, as they can act as oncogenes or tumor suppressors depending on the cancer type. However, 
these proteins can undoubtedly impact cancer progression and, therefore, can be attractive druggable targets in cancer 
therapy. 
Indeed, the last years small molecule chemical inhibitors have been designed to target mainly FTO. For instance, R-2-
hydroxyglutarate (R-2HG) halts proliferation and induces cell death, by inhibiting the function of FTO in AML and glioma 
cell lines, in vitro. In addition, the ethyl ester form of meclofenamic acid (MA2) represses tumor progression in glioblasto-
ma cells and extends survival in xenografted mice. More recently, the use of the novel FTO inhibitors FB23 and FB23-2 in 
in vivo studies for AML treatment show encouraging results, in terms of blocking AML progression in xenotransplanted 
mice.9 Although several FTO inhibitors have been designed and tested for their anti-cancer properties, similar progress 
has not been achieved concerning the develoment of inhibitors targeting METTL proteins. In fact, the first pioneer study 
describing a novel selective inhibitor of METTL3 has been published the current year. According to the results of Yankova 
et al., treating AML with STM2457, a catalytic inhibitor of METTL3, diminishes tumor growth and induces cell death in vitro 
and prolongs survival of mice in vivo.10 
In conclusion, current drug-based anti-cancer therapies include chemotherapy and, more recently, immunotherapy, which 
are the standard approaches for treating advanced malignancies. Although the use of chemotherapy has greatly improved 
the survival rates of cancer patients, a significant amount of patients develop resistance to the current treatment regi-
mens. In addition, a large proportion of patients do not benefit from current chemotherapeutic drugs used for treatment. 
Moreover, a specific drug may exhibit a favorable outcome for only one or a limited number of cancer types. Thus, the 
identification of novel molecular targets for cancer treatment is absolutely urgent. To this end, the groundbreaking ad-
vances in the field of RNA biology, during the last decade have highlighted the crucial role of RNA-modifying enzymes in 
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cancer, which can now be pharmacologically targeted with encouraging results for some cancer types, such as AML. It re-
mains a challenge to elucidate the efficacy of targeting RNA-modifying enzymes, in a large panel of cancer types, inclu-
ding solid cancers with limited success of treatment, such as pancreatic and liver cancers. Nevertheless, RNA-modifying 
enzyme inhibitors will be on their way to clinical trials in the near future and the scientific community awaits with great 
interest the outcome of these trials. 
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